Noxxon Pharma

From Wikipedia, the free encyclopedia
  (Redirected from NOXXON Pharma)
Jump to: navigation, search
Noxxon Pharma
Aktiengesellschaft
Founded 1997
Headquarters Berlin, Germany
Key people
  • Aram Mangasarian, CEO
  • J. Donald deBethizy, Chairman of the supervisory board
  • Jens P. Furste, Founder
Number of employees
10 (2017)[1]
Website www.noxxon.com

Noxxon Pharma is a small-to-medium-sized company founded in year 1997 in Berlin, Germany and since then is headquartered there. The company is member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa). The company is listed on Euronext Growth Paris (ALNOX).

Noxxon Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to natural occurring D-RNA molecules. The company calls these agents Spiegelmers,[2][3] from Spiegel, the German word for "mirror."

The L-RNA are resistant to the natural RNA nuclease enzymes.[4]

Products[edit]

While no Spiegelmer is on the market yet, some candidates are in clinical trials. NOXXON's focus is on improving cancer treatment by targeting the tumor microenvironment.

A Spiegelmer (NOX-A12, olaptesed pegol) is under development as a combination therapy for a number of cancer indications.[5][6][7]

A different Spiegelmer (NOX-E36, emapticap pegol) has been tested for the treatment of a progressive kidney disease in diabetics, Diabetic nephropathy.[8] Favorable results were reported in June, 2014 in a company press release.[9] NOX-E36 targets MCP-1, also called CCL2.[4]

A third Spiegelmer (NOX-H94) has been in a clinical trial for the treatment of Anemia of chronic disease.[10][11]

References[edit]

  1. ^ Investors. Noxxon.com. Retrieved on 2018-02-14.
  2. ^ Vater A, Klussmann S (March 2003). "Toward third-generation aptamers: Spiegelmers and their therapeutic prospects". Curr Opin Drug Discov Dev. 6 (2): 253–61. PMID 12669461. 
  3. ^ Eulberg D, et al. (2006), 18, "Spiegelmers for Therapeutic Applications" (in German), The Aptamer Handbook (WILEY-VCH): pp. 417-42, ISBN 3-527-31059-2 
  4. ^ a b Aram Mangasarian explains the elegant mirror image technology of NOXXON Pharma for extracellular targets
  5. ^ Clinical trial number NCT03168139 for "Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer" at ClinicalTrials.gov
  6. ^ Clinical trial number NCT01521533 for "NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma" at ClinicalTrials.gov
  7. ^ Clinical trial number NCT01486797 for "NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia" at ClinicalTrials.gov
  8. ^ Clinical trial number NCT01547897 for "NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria" at ClinicalTrials.gov
  9. ^ http://www.noxxon.com/downloads/pressrel/2014-06-02_NOXXONs_Emapticap_Pegol_Study_Selected_for_Late_Breaking_Clinical_Trials_Symposium.pdf.
  10. ^ Clinical trial number NCT01691040 for "Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer" at ClinicalTrials.gov
  11. ^ Schwoebel F, et al. (March 2013). "The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys". Blood. 121 (12): 2311–5. doi:10.1182/blood-2012-09-456756. PMC 3606066Freely accessible. PMID 23349391. 

External links[edit]